. 2017 Dec 23;9(2):2697–2704. doi: 10.18632/oncotarget.23627

Table 1. Survival analysis of AnxA1 and AnxA2 with clinical outcomes in patients with breast cancer (intrinsic subtypes).

Variables	Overall Survival		Relapse Free Survival		Distant Metastasis Free Survival
Variables	HR ^a(95% CI)^b	P-value^c	HR^a (95% CI)^b	P-value^c	HR ^a(95% CI)^b	P-value^c
All Breast Cancer Subtypes
AnxA1 (high vs. low)	1.02 (0.8-1.29)	0.89	1.07 (0.96-1.2)	0.22	0.95 (0.78-1.16)	0.62
AnxA2 (high vs. low)	1.04 (0.82-1.32)	0.74	1.11 (0.99-1.25)	0.067	1.05 (0.86-1.29)	0.63
AnxA6 (high vs. low)	0.8 (0.63-1.02)	0.067	0.96 (0.86-1.08)	0.52	0.87 (0.71-1.07)	0.18
Luminal A Breast Cancer
AnxA1 (high vs. low)	0.93 (0.64-1.36)	0.7	0.95 (0.8-1.14)	0.58	0.92 (0.69-1.24)	0.58
AnxA2 (high vs. low)	0.71 (0.48-1.04)	0.08	0.94 (0.79-1.12)	0.48	1 (0.74-1.35)	1
AnxA6 (high vs. low)	1.19 (0.81-1.73)	0.38	0.89 (0.75-1.06)	0.2	1.07 (0.79-1.44)	0.66
Luminal B Breast Cancer
AnxA1 (high vs. low)	0.86 (0.57-1.31)	0.49	0.92 (0.75-1.12)	0.41	0.78 (0.53-1.13)	0.19
AnxA2 (high vs. low)	1.33 (0.88-2.01)	0.18	1.12 (0.91-1.37)	0.28	1.05 (0.72-1.52)	0.81
AnxA6 (high vs. low)	0.85 (0.56-1.28)	0.43	1.07 (0.87-1.31)	0.52	0.76 (0.52-1.11)	0.16
HER2+ Breast Cancer
AnxA1 (high vs. low)	0.61 (0.28-1.33)	0.21	0.72 (0.47-1.09)	0.12	1.36 (0.71-2.59)	0.35
AnxA2 (high vs. low)	0.77 (0.36-1.65)	0.5	1.01 (0.66-1.52)	0.98	1.27 (0.66-2.42)	0.47
AnxA6 (high vs. low)	1.36 (0.63-2.94)	0.43	1.41 (0.93-2.15)	0.11	1.41 (0.74-2.71)	0.3
Triple-negative/Basal Breast Cancer
AnxA1 (high vs. low)^*	2.14 (1.22-3.78)	0.007	1.66 (1.28-2.17)	0.00014	1.33 (0.79-2.24)	0.27
AnxA2 (high vs. low)^*	2.66 (1.14-6.25)	0.019	1.45 (1.12-1.89)	0.0051	1.5 (1.16-1.95)	0.0021
AnxA6 (high vs. low)^*	0.43 (0.24-0.76)	0.003	1.34(1.03-1.74)	0.028	0.54 (0.32-0.91)	0.019

^a HR=Hazard Ratio.

^b CI= Confidence Interval.

^c P-value = P < 0.05 considered significant.

^* = Significant genes (Genes and subtypes in bold to indicate preference for subtype).